David C. Harmon

9.5k total citations · 1 hit paper
128 papers, 7.1k citations indexed

About

David C. Harmon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology. According to data from OpenAlex, David C. Harmon has authored 128 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pulmonary and Respiratory Medicine, 48 papers in Oncology and 31 papers in Rheumatology. Recurrent topics in David C. Harmon's work include Sarcoma Diagnosis and Treatment (68 papers), Vascular Tumors and Angiosarcomas (26 papers) and Bone Tumor Diagnosis and Treatments (22 papers). David C. Harmon is often cited by papers focused on Sarcoma Diagnosis and Treatment (68 papers), Vascular Tumors and Angiosarcomas (26 papers) and Bone Tumor Diagnosis and Treatments (22 papers). David C. Harmon collaborates with scholars based in United States, China and Spain. David C. Harmon's co-authors include Francis J. Hornicek, Henry J. Mankin, Edwin Choy, Thomas F. DeLaney, Herman D. Suit, Andrew E. Rosenberg, G. Petur Nielsen, Zhenfeng Duan, Robert G. Maki and Mark C. Gebhardt and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

David C. Harmon

126 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

2007 531 citations Robert G. Maki, J. Kyle Wathen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David C. Harmon United States	52	4.6k	3.1k	1.6k	1.3k	1.3k	128	7.1k
Sant P. Chawla United States	50	5.4k 1.2×	3.9k 1.3×	2.3k 1.5×	1.2k 0.9×	1.9k 1.5×	300	9.7k
Jonathan C. Trent United States	48	5.1k 1.1×	2.5k 0.8×	1000 0.6×	756 0.6×	1.3k 1.1×	283	8.2k
Scott H. Okuno United States	42	3.6k 0.8×	2.5k 0.8×	738 0.5×	1.0k 0.8×	959 0.8×	178	5.8k
Stefano Ferrari Italy	56	7.3k 1.6×	2.8k 0.9×	3.5k 2.2×	1.7k 1.3×	2.0k 1.6×	206	10.0k
Axel Le Cesne France	56	7.9k 1.7×	4.3k 1.4×	2.1k 1.3×	1.9k 1.5×	1.1k 0.9×	270	10.6k
Suzanne George United States	55	6.8k 1.5×	3.7k 1.2×	863 0.5×	1.3k 1.0×	1.8k 1.4×	257	11.7k
Gerald Rosen United States	45	6.1k 1.3×	2.6k 0.8×	2.8k 1.7×	1.7k 1.3×	672 0.5×	155	8.3k
Vivien Bramwell Canada	32	2.6k 0.6×	2.4k 0.8×	730 0.5×	514 0.4×	942 0.8×	75	5.1k
Martin E. Blackstein Canada	37	3.9k 0.9×	2.0k 0.6×	736 0.5×	428 0.3×	1.0k 0.8×	101	6.3k
Binh Bui France	28	3.4k 0.7×	2.3k 0.7×	762 0.5×	1.3k 1.0×	600 0.5×	56	4.6k

Countries citing papers authored by David C. Harmon

Since Specialization

Citations

This map shows the geographic impact of David C. Harmon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Harmon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Harmon more than expected).

Fields of papers citing papers by David C. Harmon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Harmon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Harmon. The network helps show where David C. Harmon may publish in the future.

Co-authorship network of co-authors of David C. Harmon

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Harmon. A scholar is included among the top collaborators of David C. Harmon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Harmon. David C. Harmon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harmon, David C., et al.. (2024). Preadmission Metformin Use Is Associated with Reduced Mortality in Patients with Diabetes Mellitus Hospitalized with COVID-19. Journal of General Internal Medicine. 39(16). 3253–3260. 1 indexed citations

Gao, Yan, Yunfei Liao, Jacson Shen, et al.. (2016). Evaluation of P‐glycoprotein (Pgp) expression in human osteosarcoma by high‐throughput tissue microarray. Journal of Orthopaedic Research®. 34(9). 1606–1612. 14 indexed citations

Yang, Xiaoqian, Yong Feng, Yan Gao, et al.. (2015). NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecologic Oncology. 137(1). 134–142. 10 indexed citations

Shen, Jacson, Gregory M. Coté, Edwin Choy, et al.. (2014). Programmed Cell Death Ligand 1 Expression in Osteosarcoma. Cancer Immunology Research. 2(7). 690–698. 154 indexed citations

Duan, Zhenfeng, Jianming Zhang, Shunan Ye, et al.. (2014). A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer. 14(1). 681–681. 27 indexed citations

Choy, Edwin, James E. Butrynski, David C. Harmon, et al.. (2014). Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 14(1). 813–813. 117 indexed citations

Duan, Zhenfeng, Jianming Zhang, Edwin Choy, et al.. (2012). Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation. Clinical Cancer Research. 18(17). 4580–4588. 60 indexed citations

Schwab, Pascale, et al.. (2012). A 55‐year‐old woman with orbital inflammation. Arthritis Care & Research. 64(11). 1776–1782. 9 indexed citations

Liu, Xianzhe, Edwin Choy, Francis J. Hornicek, et al.. (2011). ROCK1 as a potential therapeutic target in osteosarcoma. Journal of Orthopaedic Research®. 29(8). 1259–1266. 69 indexed citations

10.

Mullen, John T., Wendy Kobayashi, Jing Jing Wang, et al.. (2011). Long‐term follow‐up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 118(15). 3758–3765. 64 indexed citations

11.

Duan, Zhenfeng, Edwin Choy, David C. Harmon, et al.. (2009). Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Molecular Cancer Therapeutics. 8(8). 2122–2130. 76 indexed citations

12.

George, Suzanne, Priscilla Merriam, Robert G. Maki, et al.. (2009). Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. Journal of Clinical Oncology. 27(19). 3154–3160. 249 indexed citations

13.

Duan, Zhenfeng, Edwin Choy, David C. Harmon, et al.. (2009). ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines. PLoS ONE. 4(9). e6967–e6967. 16 indexed citations

14.

Maki, Robert G., J. Kyle Wathen, Shreyaskumar Patel, et al.. (2007). Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. Journal of Clinical Oncology. 25(19). 2755–2763. 531 indexed citations breakdown →

15.

Dileo, Palma, Jeffrey A. Morgan, David Zahrieh, et al.. (2007). Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas. Cancer. 109(9). 1863–1869. 56 indexed citations

16.

Mohiuddin, Majid, David C. Harmon, & Thomas F. DeLaney. (2005). Severe Acute Enteritis in a Multiple Myeloma Patient Receiving Bortezomib and Spinal Radiotherapy: Case Report. Journal of Chemotherapy. 17(3). 343–346. 10 indexed citations

17.

García‐Carbonero, Rocio, Judith Manola, Michael V. Seiden, et al.. (2004). Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. Journal of Clinical Oncology. 22(8). 1480–1490. 250 indexed citations

18.

Puchalski, Thomas A., David P. Ryan, Rocio García‐Carbonero, et al.. (2002). Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemotherapy and Pharmacology. 50(4). 309–319. 55 indexed citations

19.

Kaufman, David W., Judith P. Kelly, Theresa Anderson, David C. Harmon, & S. Shapiro. (1997). Evaluation of Case Reports of Aplastic Anemia Among Patients Treated with Felbamate. Epilepsia. 38(12). 1265–1269. 97 indexed citations

20.

Suit, Herman D., Henry J. Mankin, W. C. Wood, et al.. (1988). Treatment of the patient with stage M0 soft tissue sarcoma.. Journal of Clinical Oncology. 6(5). 854–862. 210 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact